Open
| Close
| High
| Low
| Previous Close
| Daily Price Gain
|
YTD High
| YTD High Date
| YTD Low
| YTD Low Date
| YTD Price Change
| YTD Gain
|
52 Week High
| 52 Week High Date
| 52 Week Low
| 52 Week Low Date
| 52 Week Price Change
| 52 Week Gain
|
Stock Symbol
| Exchange
| Company URL
| Company Phone
|
CEO
| Headquarters
| Business Address
| |
Sector
| Industry Category
| Industry Group
| CIK
|
About
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | |||
Description
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California. |